Skip to main content

Table 6 Relative risk for site of first recurrence by breast cancer subtype in 300 women

From: Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer

Site TNBC (n = 57) HER2 (n = 37) ER/PR/HER2 (n = 28) ER/PR (n = 178)
  RR/CI p RR/CI p RR/CI p RR/CI p
Lung 0.959/0.49–1.84 0.901 0.655/0.36–1.19 0.166 0.495/0.22–1.11 0.083 1.399/0.82–2.35 0.207
Bone 0.554/0.30–1.00 0.052 0.708/0.40–0.23 0.223 1.159/0.53–2.52 0.710 1.849/1.15–2.95 0.010
Brain 2.493/1.04–5.92 0.034 2.489/1.07–5.78 0.030 3.436/1.25–9.44 0.024 0.222/0.09–0.54 <0.001
Liver 1.439/0.76–2.70 0.256 4.897/2.71–8.82 <0.001 1.70/0.74–3.86 0.201 0.220/0.12–0.38 <0.001
LN 1.641/0.85–3.13 0.131 2.160/1.17–3.96 0.012 1.748/0.75–4.06 0.191 0.397/0.22–0.69 0.001
Skin 1.112/0.53–2.32 0.777 0.577/0.25–1.29 0.177 0.740/0.24–2.22 0.551 1.327/0.71–2.45 0.365
  1. CI 95 % confidence interval, RR relative risk, TNBC triple-negative breast cancer